Efficacy and tolerability of pharmacotherapies for attention-deficit hyperactivity disorder in adults (Q28246506)

attention deficit hyperactivity disorder

Europe PubMed Central

title

Efficacy and tolerability of pharmacotherapies for attention-deficit hyperactivity disorder in adults (English)

0 references

main subject

pharmacotherapy

0 references

0 references

1 reference

Paramala J Santosh

1

0 references

Sanjida Sattar

series ordinal

2

0 references

Myooran Canagaratnam

series ordinal

3

0 references

language of work or name

English

0 references

publication date

1 September 2011

0 references

published in

CNS Drugs

0 references

volume

25

0 references

issue

9

0 references

page(s)

737-63

0 references

cites work

Diagnostic controversies in adult attention deficit hyperactivity disorder

1 reference

https://api.crossref.org/works/10.2165%2F11593070-000000000-00000

Young adult outcome of attention deficit hyperactivity disorder: a controlled 10-year follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593070-000000000-00000

Attention-deficit/hyperactivity disorder in adults: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593070-000000000-00000

Is ADHD a valid diagnosis in adults? No.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593070-000000000-00000

Cross-national prevalence and correlates of adult attention-deficit hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593070-000000000-00000

The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593070-000000000-00000

Age-dependent decline of symptoms of attention deficit hyperactivity disorder: impact of remission definition and symptom type.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593070-000000000-00000

Psychiatric comorbidity in adult attention deficit hyperactivity disorder: findings from multiplex families.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593070-000000000-00000

Families of children with attention-deficit/hyperactivity disorder: review and recommendations for future research

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593070-000000000-00000

Driving impairments in teens and adults with attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593070-000000000-00000

Practice Parameter for the Assessment and Treatment of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593070-000000000-00000

A large, double-blind, randomized clinical trial of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593070-000000000-00000

Efficacy and safety of methylphenidate in 45 adults with attention-deficit/hyperactivity disorder. A randomized placebo-controlled double-blind cross-over trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593070-000000000-00000

An experimental comparison of Pycnogenol and methylphenidate in adults with Attention-Deficit/Hyperactivity Disorder (ADHD).

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593070-000000000-00000

A controlled trial of methylphenidate in adults with attention deficit/hyperactivity disorder and substance use disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593070-000000000-00000

Comparing guanfacine and dextroamphetamine for the treatment of adult attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593070-000000000-00000

Efficacy of a mixed amphetamine salts compound in adults with attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593070-000000000-00000

Meta-analysis of the efficacy of methylphenidate for treating adult attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593070-000000000-00000

Limits of meta-analysis: methylphenidate in the treatment of adult attention-deficit hyperactivity disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593070-000000000-00000

Methylphenidate significantly improves driving performance of adults with attention-deficit hyperactivity disorder: a randomized crossover trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593070-000000000-00000

Safety of therapeutic methylphenidate in adults: a systematic review of the evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593070-000000000-00000

Effects of chronic nicotine and methylphenidate in adults with attention deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593070-000000000-00000

A randomised, placebo-controlled, 24-week, study of low-dose extended-release methylphenidate in adults with attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593070-000000000-00000

A randomized, placebo-controlled trial of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593070-000000000-00000

A randomized, placebo-controlled trial of three fixed dosages of prolonged-release OROS methylphenidate in adults with attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593070-000000000-00000

Efficacy and safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, double-blind, parallel group, dose-escalation study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593070-000000000-00000

Treatment of methadone-maintained patients with adult ADHD: double-blind comparison of methylphenidate, bupropion and placebo

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593070-000000000-00000

Treatment of cocaine dependent treatment seekers with adult ADHD: double-blind comparison of methylphenidate and placebo.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593070-000000000-00000

Sustained release methylphenidate for the treatment of ADHD in amphetamine abusers: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593070-000000000-00000

Efficacy and safety of dexmethylphenidate extended-release capsules in adults with attention-deficit/hyperactivity disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593070-000000000-00000

Long-acting medications for the hyperkinetic disorders. A systematic review and European treatment guideline

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593070-000000000-00000

Efficacy of osmotic-release oral system (OROS) methylphenidate for mothers with attention-deficit/hyperactivity disorder (ADHD): preliminary report of effects on ADHD symptoms and parenting

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593070-000000000-00000

Long-term effectiveness and safety of dexmethylphenidate extended-release capsules in adult ADHD.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593070-000000000-00000

Long-term safety and effectiveness of lisdexamfetamine dimesylate in adults with attention-deficit/ hyperactivity disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593070-000000000-00000

Short-term effects of lisdexamfetamine dimesylate on cardiovascular parameters in a 4-week clinical trial in adults with attention-deficit/hyperactivity disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593070-000000000-00000

Effectiveness and tolerability of tomoxetine in adults with attention deficit hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593070-000000000-00000

Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593070-000000000-00000

Once-daily atomoxetine for adult attention-deficit/hyperactivity disorder: a 6-month, double-blind trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593070-000000000-00000

Atomoxetine treatment in adults with attention-deficit/hyperactivity disorder and comorbid social anxiety disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593070-000000000-00000

A controlled clinical trial of bupropion for attention deficit hyperactivity disorder in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593070-000000000-00000

Bupropion XL in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593070-000000000-00000

ABT-089, a neuronal nicotinic receptor partial agonist, for the treatment of attention-deficit/hyperactivity disorder in adults: results of a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593070-000000000-00000

A double-blind comparison of galantamine hydrogen bromide and placebo in adults with attention-deficit/hyperactivity disorder: a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593070-000000000-00000

Cardiovascular effects of therapeutic doses of tricyclic antidepressants in children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593070-000000000-00000

Emotional dysregulation in adult ADHD and response to atomoxetine.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593070-000000000-00000

Open-label trial of atomoxetine hydrochloride in adults with ADHD.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593070-000000000-00000

Long-term, open-label safety and efficacy of atomoxetine in adults with ADHD: final report of a 4-year study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593070-000000000-00000

Atomoxetine treatment of adults with ADHD and comorbid alcohol use disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593070-000000000-00000

Safety and tolerability of once versus twice daily atomoxetine in adults with ADHD.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593070-000000000-00000

Six-week, double-blind, placebo-controlled study of desipramine for adult attention deficit hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593070-000000000-00000

Non-stimulant treatments for ADHD.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593070-000000000-00000

Sudden death in children receiving Norpramin: a review of three reported cases and commentary

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593070-000000000-00000

Cigarette smoking in adult patients diagnosed with attention deficit hyperactivity disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593070-000000000-00000

Venlafaxine versus stimulant therapy in patients with dual diagnosis ADD and depression

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593070-000000000-00000

Reboxetine versus methylphenidate in treatment of children and adolescents with attention deficit-hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593070-000000000-00000

Improvement with duloxetine in an adult ADHD patient

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593070-000000000-00000

Comparative benefits and harms of competing medications for adults with attention-deficit hyperactivity disorder: a systematic review and indirect comparison meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593070-000000000-00000

A comparison of the efficacy of medications for adult attention-deficit/hyperactivity disorder using meta-analysis of effect sizes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593070-000000000-00000

Comparing the efficacy of stimulants for ADHD in children and adolescents using meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593070-000000000-00000

Attention deficit hyperactivity disorder in sport: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593070-000000000-00000

ADHD in adults: a review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593070-000000000-00000

A combined treatment approach for adults with ADHD--results of an open study of 43 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593070-000000000-00000

Psychosocial treatments for ADHD in teens and adults: a practice-friendly review

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593070-000000000-00000

Prevalence of attention deficit-/hyperactivity disorder (ADHD) and comorbid disorders in young male prison inmates

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593070-000000000-00000

Age-dependent decline of attention deficit hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593070-000000000-00000

Propranolol for adults with temper outbursts and residual attention deficit disorder.

21 January 2018

1 reference

12 December 2020

The persistence of attention-deficit/hyperactivity disorder into young adulthood as a function of reporting source and definition of disorder

1 reference

12 December 2020

A guide to the treatment of adults with ADHD.

1 reference

12 December 2020

Long-term prognosis in attention-deficit/hyperactivity disorder

1 reference

12 December 2020

A review of the economic burden of ADHD

1 reference

12 December 2020

A randomised, double-blind, placebo-controlled trial of dexamphetamine in adults with attention deficit hyperactivity disorder

1 reference

12 December 2020

Efficacy of a novel biphasic controlled-release methylphenidate formula in adults with attention-deficit/hyperactivity disorder: results of a double-blind, placebo-controlled crossover study.

1 reference

12 December 2020

Bupropion SR vs. methylphenidate vs. placebo for attention deficit hyperactivity disorder in adults.

1 reference

12 December 2020

A double-blind, placebo-controlled, crossover study of osmotic release oral system methylphenidate in adults with ADHD with assessment of oppositional and emotional dimensions of the disorder

1 reference

12 December 2020

The Efficacy of 2 Different Dosages of Methylphenidate in Treating Adults with Attention-Deficit Hyperactivity Disorder

1 reference

12 December 2020

A pilot clinical trial of oxcarbazepine in adults with attention-deficit hyperactivity disorder

1 reference

12 December 2020

Mixed amphetamine salts extended-release in the treatment of adult ADHD: a randomized, controlled trial.

1 reference

12 December 2020

ADHD is associated with early initiation of cigarette smoking in children and adolescents

1 reference

12 December 2020

Efficacy of modafinil compared to dextroamphetamine for the treatment of attention deficit hyperactivity disorder in adults

1 reference

12 December 2020

Triple-bead mixed amphetamine salts (SPD465), a novel, enhanced extended-release amphetamine formulation for the treatment of adults with ADHD: a randomized, double-blind, multicenter, placebo-controlled study

1 reference

12 December 2020

Sibling accounts of attention deficit hyperactivity disorder (ADHD)

1 reference

12 December 2020

A pilot controlled clinical trial of ABT-418, a cholinergic agonist, in the treatment of adults with attention deficit hyperactivity disorder

1 reference

12 December 2020

A randomized controlled trial of a novel mixed monoamine reuptake inhibitor in adults with ADHD

1 reference

12 December 2020

Do individuals with ADHD self-medicate with cigarettes and substances of abuse? Results from a controlled family study of ADHD.

1 reference

12 December 2020

A randomized, double-blind, crossover study of methylphenidate and lithium in adults with attention-deficit/hyperactivity disorder: preliminary findings

1 reference

12 December 2020

Double-blind placebo-controlled trial of methylphenidate in the treatment of adult ADHD patients with comorbid cocaine dependence

1 reference

12 December 2020

A randomized double-blind trial of paroxetine and/or dextroamphetamine and problem-focused therapy for attention-deficit/hyperactivity disorder in adults.

1 reference

12 December 2020

Adults with attention-deficit/hyperactivity disorder: a controversial diagnosis.

1 reference

12 December 2020

Psychotherapy of attention deficit hyperactivity disorder in adults--a pilot study using a structured skills training program

1 reference

12 December 2020

Double-blind, placebo-controlled study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder.

1 reference

12 December 2020

The effects of attention-deficit/hyperactivity disorder on employment and household income.

1 reference

12 December 2020